E-mail us Sitemap ruslv

News / 03 JUNE 2017

Distributor days for CIS countries by Amgen / modern therapy of osteoporosis

From May 31 to June 2, distributor days for CIS countries organized by Amgen were held in Tbilisi. AlenMed Promotion SIA, the exclusive distributor of Amgen in Belarus, took part in the event.

In the focus of the event were issues of modern therapy of osteoporosis. Participants discussed the current state of the problem in such countries as Russia, Belarus, Ukraine, Georgia, Armenia and Kazakhstan.

Osteoporosis is a systemic disease of the skeleton, characterized by decrease in bone mass and breakdown in the structure of bone tissue, which ultimately leads to increased fragility of bones with a tendency to fracture. The process often develops in the elderly, when the loss of bone mass is rapidly occurring. However, the most vulnerable category are postmenopausal women, with hormonal changes in the body. Also patients with breast cancer, prostate gland, receiving long-term hormone-deprivation therapy, are susceptible to reducing of the density of bone tissue. Many other diseases can be the cause of secondary osteoporosis, for example, diabetes mellitus, liver and kidney disease, thyroid and parathyroid glands. Development of osteoporosis is also facilitated by long-term use of glucocorticoids.

Osteoporosis is a common disabling disease, which incidence is growing and the danger is underestimated. The most frequent areas of osteoporotic fractures are the vertebrae, the neck of the hip, and the wrist. According to statistics, this pathology affects every third woman at the age of 50 years, every 5 patients die within the first year following the fracture of the femoral neck, and more than half of the patients after a fracture of the femoral neck lose their ability to move independently after a year. 8 out of 10 women do not receive treatment for a fracture associated with osteoporosis.

In the context of this problem, the prospects of using the drug "Prolia" (denosumab) produced by Amgen, which is the first monoclonal antibody designed for effective therapy of osteoporosis, were discussed.


Back to news
All news | June 2017 | April 2017 | April 2016 | January 2016 | December 2015 | October 2015 | July 2015 | June 2015 | April 2015 | December 2014 | September 2014 | April 2014 | March 2014 | January 2014 | November 2013 | July 2013 | May 2013 | March 2013 | February 2013 | October 2012 | September 2012 | May 2012 | April 2012 | July 2011 | June 2011 | March 2011 | November 2010 | October 2010 | September 2010 | April 2010 | November 2009 | September 2009 | July 2009 | May 2009 | April 2009 | March 2009 | February 2009 | November 2008 | October 2008 | March 2008 | January 2008